

Judith A Siuciak

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4284706/judith-a-siuciak-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48
papers

4,755
citations

31
h-index

49
g-index

49
ext. papers

5,074
ext. citations

4.8
avg, IF

4.77
L-index

#	Paper	IF	Citations
48	Soluble BACE-1 Activity and sAPP β Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 431-40	4.3	23
47	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2013 , 9, e111-94	1.2	296
46	Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. <i>Archives of Neurology</i> , 2012 , 69, 1310-7		142
45	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2012 , 8, S1-68	1.2	368
44	Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1114-21	11.6	64
43	1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosis. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 1724-39	8.3	24
42	Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 4536-47	8.3	46
41	3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009 , 19, 2524-9	2.9	29
40	Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxy-methyl]-quinoline (PF-2545920) for the treatment of schizophrenia. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 5188-96	8.3	175
39	The role of phosphodiesterases in schizophrenia : therapeutic implications. <i>CNS Drugs</i> , 2008 , 22, 983-93	6.7	78
38	Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background. <i>Neuropharmacology</i> , 2008 , 54, 417-27	5.5	50
37	Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008 , 325, 681-90	4.7	240
36	Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. <i>Psychopharmacology</i> , 2008 , 197, 115-26	4.7	87
35	Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. <i>Psychopharmacology</i> , 2007 , 192, 415-24	4.7	75
34	Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits. <i>Psychopharmacology</i> , 2007 , 194, 185-95	4.7	45
33	CP-809,101, a selective 5-HT _{2C} agonist, shows activity in animal models of antipsychotic activity. <i>Neuropharmacology</i> , 2007 , 52, 279-90	5.5	120
32	Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. <i>Neuropharmacology</i> , 2007 , 53, 113-24	5.5	48

31	Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia. <i>Expert Opinion on Drug Discovery</i> , 2007 , 2, 1001-9	6.2	16
30	Treating neuropsychiatric disorders with PDE10A inhibitors. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006 , 3, 527-532		7
29	Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. <i>Neuropharmacology</i> , 2006 , 51, 374-85	5.5	200
28	Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. <i>Neuropharmacology</i> , 2006 , 51, 386-96	5.5	234
27	The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. <i>Psychopharmacology</i> , 2004 , 175, 163-9	4.7	49
26	Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression.. <i>Behavioral Neuroscience</i> , 2001 , 115, 1145-1153	2.1	185
25	Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. <i>Neuroscience</i> , 1999 , 89, 157-66	3.9	239
24	Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. <i>Annals of Neurology</i> , 1998 , 43, 46-55	9.4	114
23	BDNF induction of tryptophan hydroxylase mRNA levels in the rat brain. <i>Journal of Neuroscience Research</i> , 1998 , 52, 149-58	4.4	95
22	Co-infusion with a TrkB-Fc receptor body carrier enhances BDNF distribution in the adult rat brain. <i>Experimental Neurology</i> , 1998 , 152, 20-33	5.7	45
21	Effects of BDNF infusion on the regulation of TrkB protein and message in adult rat brain. <i>Experimental Neurology</i> , 1997 , 145, 62-70	5.7	77
20	Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). <i>Pharmacology Biochemistry and Behavior</i> , 1997 , 56, 131-7	3.9	702
19	Localization of 2-[125I]iodomelatonin binding sites in visual areas of the turtle brain. <i>European Journal of Pharmacology</i> , 1996 , 297, 181-5	5.3	3
18	BDNF increases monoaminergic activity in rat brain following intracerebroventricular or intraparenchymal administration. <i>Brain Research</i> , 1996 , 710, 11-20	3.7	190
17	Local infusion of brain-derived neurotrophic factor modifies the firing pattern of dorsal raphe serotonergic neurons. <i>Brain Research</i> , 1996 , 712, 293-8	3.7	67
16	BDNF produces analgesia in the formalin test and modifies neuropeptide levels in rat brain and spinal cord areas associated with nociception. <i>European Journal of Neuroscience</i> , 1995 , 7, 663-70	3.5	75
15	In situ hybridization of trkB and trkC receptor mRNA in rat forebrain and association with high-affinity binding of [125I]BDNF, [125I]NT-4/5 and [125I]NT-3. <i>European Journal of Neuroscience</i> , 1994 , 6, 1389-405	3.5	181
14	Antinociceptive effect of brain-derived neurotrophic factor and neurotrophin-3. <i>Brain Research</i> , 1994 , 633, 326-30	3.7	141

13	Unilateral optic nerve transection decreases 2-[125I]-iodomelatonin binding in retinorecipient areas and visual pathways of chick brain. <i>Brain Research</i> , 1994 , 654, 63-74	3.7	10
12	Effect of pinealectomy and the light/dark cycle on 2-[125I]iodomelatonin binding in the chick optic tectum. <i>Cellular and Molecular Neurobiology</i> , 1993 , 13, 193-202	4.6	12
11	Optic nerve transection decreases 2-[125I]iodomelatonin binding in the chick optic tectum. <i>Brain Research</i> , 1992 , 590, 325-8	3.7	6
10	Avian brain epinephrine and 5-hydroxytryptamine: is it still a matter of controversy?. <i>Journal of Neurochemistry</i> , 1992 , 59, 387-8	6	3
9	Monoamines and their precursors and metabolites in the chicken brain, pineal, and retina: regional distribution and day/night variations. <i>Journal of Neurochemistry</i> , 1992 , 58, 722-9	6	26
8	The area of 2-[125I] iodomelatonin binding in the pars tuberalis of the ground squirrel is decreased during hibernation. <i>Brain Research</i> , 1991 , 557, 285-8	3.7	28
7	Localization of high affinity melatonin receptor sites in chicken brain: effect of temperature and guanine nucleotides. <i>European Journal of Pharmacology</i> , 1990 , 183, 2180	5.3	2
6	Autoradiographic localization of 2-[125I]iodomelatonin binding sites in the brains of C3H/HeN and C57BL/6J strains of mice. <i>European Journal of Pharmacology</i> , 1990 , 180, 387-90	5.3	55
5	Tolerance to the antinociceptive effect of intrathecal morphine in intact and chronic spinal rats. <i>Behavioral and Neural Biology</i> , 1990 , 54, 191-7		5
4	The synergistic effect of concurrent spinal and supraspinal opiate agonisms is reduced by both nociceptive and morphine pretreatment. <i>Pharmacology Biochemistry and Behavior</i> , 1989 , 34, 265-73	3.9	15
3	Antinociceptive effect of intrathecal morphine in tolerant and nontolerant spinal rats. <i>Pharmacology Biochemistry and Behavior</i> , 1989 , 34, 445-52	3.9	16
2	Tolerance to morphine microinjections in the periaqueductal gray (PAG) induces tolerance to systemic, but not intrathecal morphine. <i>Brain Research</i> , 1987 , 424, 311-9	3.7	47
1	Phosphodiesterase Inhibitors as a Novel Therapeutic Approach for Schizophrenia85-113		